Search Result

Results for "

ABL kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcr-Abl (78) AAK1 (1) Ack1 (1) Akt (3) Antibiotic (1) Apoptosis (16) Aurora Kinase (10) Autophagy (23) Bacterial (1) BCRP (1) c-Kit (12) c-Met/HGFR (1) c-Myc (1) CaMK (1) Casein Kinase (1) CDK (2) Cyclin G-associated Kinase (GAK) (1) Discoidin Domain Receptor (1) Drug Metabolite (3) EGFR (1) Ephrin Receptor (1) Ferroptosis (2) FGFR (6) FLT3 (7) Histone Methyltransferase (1) IGF-1R (1) Isotope-Labeled Compounds (2) JAK (6) LIM Kinase (LIMK) (2) MAP4K (1) MAPKAPK2 (MK2) (1) MNK (1) p38 MAPK (1) PDGFR (17) PKD (1) PROTACs (2) Raf (2) RET (2) Salt-inducible Kinase (SIK) (2) SARS-CoV (5) Src (23) STAT (4) Thymidylate Synthase (1) Tyrosinase (1) ULK (2) VEGFR (6) Wee1 (1)
By Research Areas:	Cancer (84) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (4)

By Targets:

Bcr-Abl (78)

AAK1 (1)

Ack1 (1)

Akt (3)

Antibiotic (1)

Apoptosis (16)

Aurora Kinase (10)

Autophagy (23)

Bacterial (1)

BCRP (1)

c-Kit (12)

c-Met/HGFR (1)

c-Myc (1)

CaMK (1)

Casein Kinase (1)

CDK (2)

Cyclin G-associated Kinase (GAK) (1)

Discoidin Domain Receptor (1)

Drug Metabolite (3)

EGFR (1)

Ephrin Receptor (1)

Ferroptosis (2)

FGFR (6)

FLT3 (7)

Histone Methyltransferase (1)

IGF-1R (1)

Isotope-Labeled Compounds (2)

JAK (6)

LIM Kinase (LIMK) (2)

MAP4K (1)

MAPKAPK2 (MK2) (1)

MNK (1)

p38 MAPK (1)

PDGFR (17)

PKD (1)

PROTACs (2)

Raf (2)

RET (2)

Salt-inducible Kinase (SIK) (2)

SARS-CoV (5)

Src (23)

STAT (4)

Thymidylate Synthase (1)

Tyrosinase (1)

ULK (2)

VEGFR (6)

Wee1 (1)

By Research Areas:

Cancer (84)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (2)

Metabolic Disease (1)

Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Bcr-Abl

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P5426

Abl protein tyrosine kinase substrate	Bcr-Abl	Others
Abl protein tyrosine kinase substrate is a biological active peptide. (Abltide is a peptide substrate for Abl Kinase (Abl protein tyrosine kinase), a partner in the gag-Abl fusion protein of the Abelson murine leukemia virus. Used in Western blot and kinase assay.)

HY-145887

BCR-ABL1-IN-1	Bcr-Abl	Neurological Disease
BCR-ABL1-IN-1 is a potent, orally active, and specific inhibitor of **ABL kinase*. BCR-ABL1-IN-1 has potential for elucidating the role of ABL* kinases in the brain in non-clinical studies .

HY-12047

Ponatinib 35+ Cited Publications AP24534	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for *Abl, PDGFRα, VEGFR2, FGFR1, and Src*, respectively .

HY-108766

Ponatinib hydrochloride 35+ Cited Publications AP24534 hydrochloride	Bcr-Abl FGFR PDGFR VEGFR Src Autophagy	Infection Cancer
Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for *Abl, PDGFRα, VEGFR2, FGFR1, and Src*, respectively .

HY-12047S

Ponatinib-d8 AP24534-d₈	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib-d₈ is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-160174

*BCR-ABL* kinase-IN-3**	Bcr-Abl	Cancer
BCR-ABL kinase-IN-3 (example 1) is a potent inhibitor of *BCR-ABL* that plays an important role in acute myeloid leukemia (AML) research .

HY-160174A

*BCR-ABL* kinase-IN-3 (dihydrocholide)**	Bcr-Abl	Cancer
BCR-ABL kinase-IN-3 (dihydrocholide) (example 1) is a potent inhibitor of *BCR-ABL* that plays an important role in acute myeloid leukemia (AML) research .

HY-18817

AFG210	Bcr-Abl FGFR Raf RET VEGFR	Cancer
AFG210 is a potent multi-target kinase inhibitor that primarily inhibits **Abl kinase (IC₅₀*=330 nM), and also has inhibitory effects on other kinases* such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of *Abl* kinase .

HY-12083

PPY-A	Bcr-Abl	Cancer
PPY-A is a potent T315I mutant and wild-type *Abl* kinases inhibitor with IC₅₀s of 9 and 20 nM, respectively. PPY-A inhibits Ba⁄F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC₅₀s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML) .

HY-12047R

Ponatinib (Standard)	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (Standard) is the analytical standard of Ponatinib. This product is intended for research and analytical applications. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for *Abl, PDGFRα, VEGFR2, FGFR1, and Src*, respectively .

HY-P1785

Abl Cytosolic Substrate ABLtide	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus .

HY-169230

BCR-ABL-IN-9	Bcr-Abl	Cancer
BCR-ABL-IN-9 (Compound B1) is a *BCR-ABL* inhibitor that achieves sustained *BCR-ABL* suppression by forming stable covalent bonds with the *ABL* kinase. BCR-ABL-IN-9 is also effective in inhibiting the activity of the *ABL* kinase (IC₅₀ = 1.2 nM). BCR-ABL-IN-9 possesses anticancer activity .

HY-169231

BCR-ABL-IN-10	Bcr-Abl	Cancer
BCR-ABL-IN-10 (compound B4) is a covalent and aryl vinyl sulfate (AVS)-containing *BCR-ABL* inhibitor with an IC₅₀ of 43.1 nM for ABL kinase. BCR-ABL-IN-10 forms a covalent and stable adduct with ABL kinase, leading to sustained inhibition of endogenous BCR-ABL activities. BCR-ABL-IN-10 can be used for the study of chronic myeloid leukemia (CML) .

HY-153008

BCR-ABL-IN-7	Bcr-Abl	Cancer
BCR-ABL-IN-7 (compound 4) is a WT and T315I mutant **ABL kinases** inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research .

HY-119370

CHMFL-ABL-121	Bcr-Abl Apoptosis	Cancer
CHMFL-ABL-121 is a highly potent type II **ABL kinase inhibitor with IC₅₀*s of 2 nM and 0.2 nM against purified inactive ABL* wt and T315I kinase protein, respectively .

HY-117718

AG957 Tyrphostin AG957; NSC 654705	Bcr-Abl	Cancer
AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity . AG957 is a *bcr/abl* kinase inhibitor with an IC₅₀ of 2.9 μM for p210 ^bcr/abl autokinase activity .

HY-18819

BCR-ABL-IN-2	Bcr-Abl	Cancer
BCR-ABL-IN-2 is an inhibitor of *BCR-ABL1* tyrosine kinase, with IC₅₀s of 57 nM, 773 nm for ABL1 ^native and ABL1 ^T315I, respectively.

HY-15728

Radotinib IY-5511	Bcr-Abl	Cancer
Radotinib(IY-5511) is a novel and selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM for wild-type BCR-ABL1 kinase.

HY-10339

KW-2449 5+ Cited Publications	FLT3 FGFR Bcr-Abl Aurora Kinase Apoptosis	Cancer
KW-2449 is a multi-targeted kinase inhibitor of FLT3, *ABL, ABL* ^T315I and Aurora kinase with IC₅₀s of 6.6, 14, 4 and 48 nM, respectively.

HY-119177

PD173956	Bcr-Abl	Others
PD173956 is a pyridopyrimidine Bcr-Abl kinase inhibitor with high selectivity for the P-loop mutant form of Bcr-Abl .

HY-150569

BCR-ABL-IN-6	Bcr-Abl	Cancer
BCR-ABL-IN-6 (9h) is a selective *Bcr-Abl* kinase inhibitor with IC₅₀s of 4.6 and 227 nM for *Bcr-Abl* ^WT and Bcr-Abl ^T3151** respectively. BCR-ABL-IN-6 inhibits *Bcr-Abl* kinase with strong affinity inside the cells with an EC₅₀ of 14.6 nM. BCR-ABL-IN-6 is an imatinib derivative which can be used for research of chronic myelogenous leukemia . BCR-ABL-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15463S1

Imatinib-d4 STI571 d₄; CGP-57148B d₄	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib-d₄ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

HY-15463S

Imatinib-d8 1 Publications Verification STI571-d₈; CGP-57148B-d₈	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

HY-10159A

Nilotinib monohydrochloride monohydrate 35+ Cited Publications AMN107 monohydrochloride monohydrate	Bcr-Abl Autophagy	Cancer
Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against *BCR-ABL, and is active against many BCR-ABL* mutants.

HY-162952

cSRC/BCR-ABL1-IN-1	Bcr-Abl	Cancer
cSRC/BCR-ABL1-IN-1 (compund 16a) is a dual-target *cSRC/BCR-ABL1* kinase inhibitor .

HY-100314

BCR-ABL-IN-1	Bcr-Abl	Cancer
BCR-ABL-IN-1 is an inhibitor of *BCR-ABL* tyrosine kinase, with a pIC₅₀ of 6.46, and may be used in the research of chronic myelogenous leukemia.

HY-126143

CHMFL-ABL-039	Bcr-Abl	Cancer
CHMFL-ABL-039 is a type II native *ABL* kinase and drug-resistant V299L mutant *BCR-ABL* inhibitor with the IC₅₀s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia .

HY-150566

BCR-ABL-IN-5	Bcr-Abl	Cancer
BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-Abl ^WT and Bcr-Abl ^T3151 with the IC₅₀ value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells .

HY-101268

CHMFL-ABL-053	Bcr-Abl Src p38 MAPK	Cancer
CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available *BCR-ABL, SRC* and p38 kinase inhibitor with IC₅₀ values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively .

HY-10159

Nilotinib 35+ Cited Publications AMN107	Bcr-Abl Autophagy	Cancer
Nilotinib is an orally available *Bcr-Abl* tyrosine kinase inhibitor with antineoplastic activity.

HY-147414

Vamotinib PF-114	Bcr-Abl	Cancer
Vamotinib (PF-114) is a potent, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis. Vamotinib shows anti-proliferative and anti-tumor activity. Vamotinib has the potential for the research of resistant philadelphia chromosome-positive (Ph+) leukemia. Vamotinib inhibits ABL series kinases with IC₅₀s of 0.49 nM (ABL), 0.78 nM (ABL ^T315I), 9.5 nM (ABL ^E255K), 2.0 nM (ABL ^F317I), 7.4 nM (ABL ^G250E), 1.0 nM (ABL ^H396P), 2.8 nM (ABL ^M351T), 12 nM (ABL ^Q252H), and 4.1 nM (ABL ^Y253F), respectively . Vamotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-50946

Imatinib Mesylate Maximum Cited Publications 99 Publications Verification STI571 Mesylate; CGP-57148B Mesylate	c-Kit Bcr-Abl PDGFR Autophagy	Cancer
Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, *Bcr-Abl, and PDGFR* (IC₅₀=100 nM) tyrosine kinases.

HY-10158

Bosutinib 20+ Cited Publications SKI-606	Src Bcr-Abl Autophagy	Cancer
Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC₅₀ of 1.2 nM and 1 nM, respectively .

HY-10158A

Bosutinib hydrate 20+ Cited Publications SKI-606 hydrate	Src Bcr-Abl	Cancer
Bosutinib hydrate is an oraly activel Src/Abl tyrosine kinase inhibito with IC₅₀ of 1.2 nM and 1 nM, respectively .

HY-15493

AN-019 NRC-AN-019	Bcr-Abl	Cancer
AN-019 is a *Bcr-Abl* kinase inhibitor. AN-019 has antitumor activity .

HY-10943

GNF-7 2 Publications Verification	Bcr-Abl Ack1	Cancer
GNF-7 is a multikinase inhibitor. GNF-7 is a *Bcr-Abl* inhibitor, with IC₅₀s of 133 nM and 61 nM for Bcr-Abl ^WT and Bcr-Abl ^T315I, respectively. GNF-7 also possesses inhibitory activity against both ACK1 (activated CDC42 kinase 1) and GCK (germinal center kinase) with IC₅₀s of 25 nM and 8 nM, respectively. GNF-7 can be used for the research of hematologic malignancies .

HY-101034

CHMFL-ABL/KIT-155 CHMFL-ABL-KIT-155	Bcr-Abl c-Kit Apoptosis PDGFR Discoidin Domain Receptor	Cancer
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC₅₀s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC₅₀=81 nM), CSF1R (IC₅₀=227 nM), DDR1 (IC₅₀=116 nM), DDR2 (IC₅₀=325 nM), LCK (IC₅₀=12 nM) and PDGFRβ (IC₅₀=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis .

HY-10159AR

Nilotinib (monohydrochloride monohydrate) (Standard)	Bcr-Abl Autophagy	Cancer
Nilotinib (monohydrochloride monohydrate) (Standard) is the analytical standard of Nilotinib (monohydrochloride monohydrate). This product is intended for research and analytical applications. Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against *BCR-ABL, and is active against many BCR-ABL* mutants.

HY-10181S

Dasatinib-d8 BMS-354825-d₈	Bcr-Abl Src Apoptosis Autophagy	Cancer
Dasatinib-d₈ is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.

HY-103032

*Multi-kinase* inhibitor 1**	PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 is a potent *multi-kinase* inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and *Bcr-abl* .

HY-108704

CT-721	Bcr-Abl	Cancer
CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC₅₀ of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities . CT-721 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-120036

Tyrphostin AG1112	Casein Kinase Tyrosinase	Cancer
Tyrphostin AG1112 is a potent inhibitors of CK II. Tyrphostin AG1112 inhibits p210 ^bcr-abl tyrosine kinase, with IC₅₀ values of 2, 15, 20 μM in p210 ^bcr-abl, EGFR and PDGFR cells, respectively .

HY-W839261

*Tyrosine kinase-IN-9*	Bcr-Abl	Neurological Disease
Tyrosine kinase-IN-9 (Compound B) is the inhibitor for *c-Abl. Tyrosine kinase*-IN-9 can be used in research of neurodegenerative diseases including Alzheimer’s and Parkinson’s disease .

HY-15463

Imatinib Maximum Cited Publications 99 Publications Verification STI571; CGP-57148B	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits *BCR/ABL, v-Abl, PDGFR* and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-103274

PD180970	Bcr-Abl Src c-Kit Apoptosis	Neurological Disease Cancer
PD180970 is a highly potent and ATP-competitive p210 ^Bcr-Abl kinase inhibitor, with an IC₅₀ of 5 nM for inhibiting the autophosphorylation of p210 ^Bcr-Abl. PD180970 also inhibits Src and KIT kinase with IC₅₀s of 0.8 nM and 50 nM, respectively. PD180970 indcues apoptosis of K562 leukemic cells, and can be used for chronic myelogenous leukemia research .

HY-10159S

Nilotinib-d6 AMN107-d₆	Bcr-Abl Autophagy	Cancer
Nilotinib-d₆ is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1].

HY-50946R

Imatinib (Mesylate) (Standard) STI571 (Mesylate) (Standard); CGP-57148B (Mesylate) (Standard)	c-Kit Bcr-Abl PDGFR Autophagy	Cancer
Imatinib (Mesylate) (Standard) is the analytical standard of Imatinib (Mesylate). This product is intended for research and analytical applications. Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, *Bcr-Abl, and PDGFR* (IC₅₀=100 nM) tyrosine kinases.

HY-15463S2

Imatinib-d3 hydrochloride STI571-d₃ hydrochloride; CGP-57148B-d₃ hydrochloride	Autophagy Bcr-Abl c-Kit SARS-CoV PDGFR	Cancer
Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-10159R

Nilotinib (Standard)	Bcr-Abl Autophagy	Cancer
Nilotinib (Standard) is the analytical standard of Nilotinib. This product is intended for research and analytical applications. Nilotinib is an orally available *Bcr-Abl* tyrosine kinase inhibitor with antineoplastic activity.

HY-132549S

Nilotinib-d3	Isotope-Labeled Compounds Bcr-Abl Autophagy	Cancer
Nilotinib-d₃ is the deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1][2].

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library

3,269 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 3,269 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

HY-L016

Protein Tyrosine Kinase Compound Library

1,259 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,259 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Cat. No.	Product Name	Target	Research Area

HY-P5426

Abl protein tyrosine kinase substrate	Bcr-Abl	Others
Abl protein tyrosine kinase substrate is a biological active peptide. (Abltide is a peptide substrate for Abl Kinase (Abl protein tyrosine kinase), a partner in the gag-Abl fusion protein of the Abelson murine leukemia virus. Used in Western blot and kinase assay.)

HY-P1785

Abl Cytosolic Substrate ABLtide	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-108486

Herbimycin A	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Source classification Benzene Quinones Disease Research Fields	Bacterial Antibiotic
Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 ^v-src and p210 ^BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.

Species:	Human (4)
Tag:	Tag Free (1) GST (3)
Source:	Sf9 insect cells (3) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P71685

	ABL1 Protein, Human (GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; ABL 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	E. coli
	ABL1, Human (GST) is a non-receptor tyrosine-protein kinase. ABL1, Human is implicated in a wide range of cellular processes, including regulation of cell growth and survival, oxidative stress and DNA-damage responses, actin dynamics and cell migration, transmission of information about the cellular environment through integrin signaling.

HY-P702716

	ABL1 Protein, Human (sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; ABL 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	Sf9 insect cells
	ABL1 is a non-receptor tyrosine protein kinase that coordinates key cellular processes for growth and survival. It affects cytoskeletal remodeling, cell motility, and receptor endocytosis. ABL1 Protein, Human (sf9) is the recombinant human-derived ABL1, expressed by Sf9 insect cells , with tag Free labeled tag. The total length of ABL1 Protein, Human (sf9) is 1104 a.a.,

HY-P77308

	ABL1 Protein, Human (sf9, GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; ABL 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	Sf9 insect cells
	ABL1 is a non-receptor tyrosine protein kinase that coordinates key cellular processes for growth and survival. It affects cytoskeletal remodeling, cell motility, and receptor endocytosis. ABL1 Protein, Human (sf9, GST) is the recombinant human-derived ABL1 protein, expressed by Sf9 insect cells , with N-GST labeled tag. The total length of ABL1 Protein, Human (sf9, GST) is 418 a.a., with molecular weight of ~65 kDa.

HY-P703085

	ARG Protein, Human (Active, Sf9, GST) Tyrosine-protein kinase ABL2; Abelson murine leukemia viral oncogene homolog 2; Abelson tyrosine-protein kinase 2; Abelson-related gene protein; Tyrosine-protein kinase ARG; ABL2; ABLL; ARG; Homo sapiens; Human kinase; Transferase; Tyrosine-protein kinase; 2.7.10.2	Human	Sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-12047S

Ponatinib-d8
Ponatinib-d₈ is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-15463S1

Imatinib-d4
Imatinib-d₄ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

HY-15463S

Imatinib-d8 1 Publications Verification
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

HY-10181S

Dasatinib-d8
Dasatinib-d₈ is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.

HY-10159S

Nilotinib-d6
Nilotinib-d₆ is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1].

HY-15463S2

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-132549S

Nilotinib-d3
Nilotinib-d₃ is the deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1][2].

HY-10159S1

Nilotinib-13C,d3
Nilotinib-13C,d3 is a deuterated labeled Nilotinib . Nilotinib is an orally available *Bcr-Abl* tyrosine kinase inhibitor with antineoplastic activity.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83458

	ABL2 Antibody (YA3203) ABL2; ABLL; ARG; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; Abelson-related gene protein; Tyrosine-protein kinase ARG	WB, FC	Human, Mouse, Rat
	ABL2 Antibody (YA3203) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3203), targeting ABL2, with a predicted molecular weight of 128 kDa (observed band size: 128 kDa). ABL2 Antibody (YA3203) can be used for WB, FC experiment in human, mouse, rat background.